Hepatitis/MASH

Novel HCV regimen shows high SVR12 rates at 8 and 12 weeks of treatment.

Dual transplant may have a protective role against cellular rejection.

Nearly 36% of graft losses are due to nonadherence in renal transplant patients.

Patients with chronic hepatitis C virus have an increased risk of developing B-cell lymphomas.

Patients with chronic hepatitis C virus have an increased risk of developing B-cell lymphomas.

Investigational injectable treatment combined with oral direct-acting antiviral drugs shows results after 8 weeks.

Renal transplant recipients eligible for medication management services under Medicare Part D had higher adherence to medication than ineligible patients.

Limiting the HCV cure to patients with advanced stages of the disease is reviewed.

Sorafenib for advanced hepatocellular carcinoma may not offer the significantly lengthened life expectancy reported in clinical trials.

Needle exchange programs offer injection drug users a nonthreatening public location to bring a dirty needle and exchange it for a sterile one.

Hepatitis C treatment administered in a community-based setting proven to be safe and effective.

Hepatitis C treatment administered in a community-based setting proven to be safe and effective.

HCV-related death reached 19,596 in 2014 as cases of new infections have more than doubled from 2010 to 2014.

Alcohol promotes faster development of fibrosis and progression to cirrhosis in people with hepatitis C virus.

Coffee consumption with high fat diet found to improve non-alcoholic fatty liver disease.

Paper device offers on-the-go inexpensive diagnosis of hepatitis C and HIV.

Antiviral therapies generate survival rates over 90% in patients with HCV-related cirrhosis.

Hepatitis B tends to be more aggressive in HIV patients, increasing the risk of cirrhosis, end-stage liver disease, and hepatocellular cancer.

Antiviral drugs can spare livers for patients with other liver diseases.

Tops news of the day from across the healthcare landscape.

Tops news of the day from across the healthcare landscape.

Coinfection with hepatitis B virus isn't uncommon among those infected with HIV.

A new treatment for hepatitis B significantly reduced viral load in 4 weeks.

A new treatment for hepatitis B significantly reduced viral load in 4 weeks.

Prognostic model provides simple and accurate clinical description for each HCC patient.